Professor Dame Pamela Shaw joins the scientific advisory board

Samsara Therapeutics, the autophagy biotech company, has appointed eminent neurologist and world-leading researcher in Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND) Professor Dame Pamela Shaw to its scientific advisory board.

Samsara Therapeutics Parkinson’s drug receives funding boost from The Michael J. Fox Foundation

Samsara Therapeutics announced today that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to further its research into a promising Parkinson’s disease drug.

Samsara Therapeutics unveils promising autophagy drug candidate, offering new hope for people with Parkinson’s and ALS

Samsara Therapeutics is first in the race to find a viable, potent autophagy inducing drug, with the potential to give us longer and healthier lives.

Meet the Neuro Team – Modelling Neurodegeneration in a Dish

CMT Research Foundation and Samsara Therapeutics Partner on a Novel Therapeutic Approach for CMT1A with the Potential to Reach Clinical Trials

CMT Research Foundation and Samsara Therapeutics Partner on a Novel Therapeutic Approach for CMT1A with the Potential to Reach Clinical Trials

Meet Nicole – From Books to Bench

Samsara Therapeutics Establishes Scientific Advisory Board

Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics

More additions to the Samsara Therapeutics team

We’re pleased to report that we’ve further strengthened our team in Oxford.

Neurodegeneration, lysosomal dysfunction and autophagy

New home and strengthening our scientific team

It’s a busy time for Samsara Therapeutics as we move into our new purpose-built labs and offices in the Wood Centre for Innovation in Oxford.

IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms (2021) Journal for Immunotherapy of Cancer

Autophagy, healthspan and lifespan